Home
Live Updates
Reata Stock Surges. Biogen Is Buying It for $7.3 Billion in Cash. : comparemela.com
Reata Stock Surges. Biogen Is Buying It for $7.3 Billion in Cash.
Biogen will acquire Reata for $172.50 a share in cash, expanding its portfolio of neuromuscular disease treatments.
Related Keywords
Christopher Viehbacher ,
Adam Glanzman Bloomberg ,
Adam Clark ,
Reata Pharmaceuticals ,
Article Normal ,
Biotechnology Services ,
Pharmaceuticals ,
Banking ,
Commercial Banking ,
Financial Investment Services ,
Portfolio Fund Asset Management ,
Healthcare Life Sciences ,
Biopharmaceuticals ,
Banking Credit ,
Financial Services ,
Investing Securities ,
Ownership Changes ,
Acquisitions Mergers Shareholdings ,
Acquisitions Mergers ,
Corporate Actions ,
Corporate Industrial News ,
Content Types ,
Factiva Filters ,
C Amp Ampe Industry News Filter ,
Synd ,
M Amp A ,
Markets ,
North America ,
Biotech And Pharma ,
Rapid Response ,
Healthcare ,
Reata Pharmaceuticals Cl A ,
Greta ,
Biogen ,
Biib ,
Acquisitions ,
Mergers ,
Shareholdings ,
Corporate ,
Industrial News ,
Portfolio ,
Fund ,
Asset Management ,
Life Sciences ,
Credit ,
Investing ,
Securities ,
comparemela.com © 2020. All Rights Reserved.